nach oben

Erschienen in:

01.06.2005 | Article

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes

verfasst von: Anne Hiukka, Jamila Fruchart-Najib, Eeva Leinonen, Hannele Hilden, Jean-Charles Fruchart, Marja-Riitta Taskinen

Erschienen in: Diabetologia | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Very low density lipoprotein (VLDL) particles are heterogeneous, comprising two main subspecies, VLDL 1 (Sf 60-400) and VLDL 2 (Sf 20-60). The aim of the study was to examine the distribution and composition of VLDL subspecies in type 2 diabetes.

Subjects, materials and methods

We studied the composition and concentration of triglyceride-rich lipoproteins (TRLs) in 217 type 2 diabetic patients and 93 control subjects between 50 and 75 years of age. Lipoprotein subspecies were separated by density-gradient ultracentrifugation. Apolipoprotein (apo) CIII and apo E in plasma and apo CIII in TRL subspecies were measured by nephelometry and apo CII in serum by a commercial kit using a single radial immunodiffusion method.

Results

The concentrations of VLDL 1, VLDL 2 and intermediate density lipoprotein were significantly increased in type 2 diabetes subjects, the change being most marked for VLDL 1. There was a strong linear correlation between VLDL 1 triglycerides and plasma triglycerides in both groups (r=0.879, p<0.001 and r=0.899, p<0.001). Diabetic subjects had markedly higher plasma ratios of apo CII:apo CIII and apo CIII:apo E. Despite elevated plasma apo CIII, type 2 diabetic subjects had a relative deficiency of apo CIII in all TRL subspecies, suggesting profound disturbances of apo CIII metabolism.

Conclusions/interpretation

The elevation of VLDL 1 triglycerides is the major determinant of plasma triglyceride concentration in normal subjects and in type 2 diabetic individuals. Both apo CIII and apo E metabolism are disturbed in type 2 diabetes.

Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M (1997) Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354–1359PubMed

Turner RC, Millns H, Neil HA et al (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) [comment]. BMJ 316:823–828PubMed

Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749CrossRefPubMed

Criqui MH, Heiss G, Cohn R et al (1993) Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328:1220–1225CrossRefPubMed

Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219PubMed

Avins AL, Neuhaus JM (2000) Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 160:1937–1944CrossRefPubMed

Bos G, Dekker JM, Nijpels G et al (2003) A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism—The Hoorn study. Diabetologia 46:910–916CrossRefPubMed

Packard CJ, Shepherd J (1997) Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17:3542–3556PubMed

Malmstrom R, Packard CJ, Caslake M et al (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454–462CrossRefPubMed

10.

Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484PubMed

11.

Marcoux C, Tremblay M, Fredenrich A, Davignon J, Cohn JS (2001) Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism 50:112–119CrossRefPubMed

12.

Campos H, Perlov D, Khoo C, Sacks FM (2001) Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 42:1239–1249PubMed

13.

van Dijk KW, Rensen PC, Voshol PJ, Havekes LM (2004) The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol 15:239–246CrossRefPubMed

14.

Briones ER, Mao SJ, Palumbo PJ, O’Fallon WM, Chenoweth W, Kottke BA (1984) Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics. Metabolism 33:42–49CrossRefPubMed

15.

Stalenhoef AF, Demacker PN, Lutterman JA, van’t Laar A (1982) Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia. Diabetologia 22:489–491CrossRefPubMed

16.

Pan XR, Cheung MC, Walden CE, Hu SX, Bierman EL, Albers JJ (1986) Abnormal composition of apoproteins C-I, C-II, and C-III in plasma and very-low-density lipoproteins of non-insulin-dependent diabetic. Chinese Clin Chem 32:1914–1920

17.

Ishibashi S, Yamada N, Shimano H, Takaku F, Akanuma Y, Murase T (1989) Composition of very-low-density lipoproteins in non-insulin-dependent diabetes mellitus. Clin Chem 35:808–812PubMed

18.

Gervaise N, Garrigue MA, Lasfargues G, Lecomte P (2000) Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 43:703–708CrossRefPubMed

19.

Luc G, Fievet C, Arveiler D et al (1996) Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res 37:508–517PubMed

20.

Sacks FM, Alaupovic P, Moye LA et al (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102:1886–1892PubMed

21.

Onat A, Hergenc G, Sansoy V et al (2003) Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 168:81–89CrossRefPubMed

22.

Santamarina-Fojo S (1992) Genetic dyslipoproteinemias: role of lipoprotein lipase and apolipoprotein C-II. Curr Opin Lipidol 3:186–195

23.

Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC (1995) Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 15:963–971PubMed

24.

Ji ZS, Dichek HL, Miranda RD, Mahley RW (1997) Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem 272:31285–31292CrossRefPubMed

25.

Mensenkamp AR, Jong MC, van Goor H et al (1999) Apolipoprotein E participates in the regulation of very low density lipoprotein–triglyceride secretion by the liver. J Biol Chem 274:35711–35718CrossRefPubMed

26.

Heeren J, Grewal T, Laatsch A et al (2003) Recycling of apoprotein E is associated with cholesterol efflux and high-density lipoprotein internalization. J Biol Chem 278:14370–14378CrossRefPubMed

27.

Keech AC, Field Study Investigators T (2004) The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study ISRCTN64783481. Cardiovasc Diabetol 3:9CrossRefPubMed

28.

World Health Organisation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation: Part I. Diagnosis and classification of diabetes mellitus. World Health Organisation, Geneva, pp 1–65

29.

Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki-Jarvinen H (1988) Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8:168–177PubMed

30.

Taskinen MR, Packard CJ, Shepherd J (1990) Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 39:1017–1027PubMed

31.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMed

32.

Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E (1987) A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 28:455–463PubMed

33.

Schonfeld G, George PK, Miller J, Reilly P, Witztum J (1979) Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 28:1001–1010CrossRefPubMed

34.

Havel RJ, Kotite L, Vigne JL et al (1980) Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E: concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J Clin Invest 66:1351–1362PubMed

35.

Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ (2001) Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 21:282–288PubMed

36.

Garvey WT, Kwon S, Zheng D et al (2003) Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453–462PubMed

37.

McEneny J, O’Kane MJ, Moles KW et al (2000) Very low density lipoprotein subfractions in type II diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia 43:485–493CrossRefPubMed

38.

Taskinen MR, Beltz WF, Harper I et al (1986) Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism: studies before and after sulfonylurea therapy. Diabetes 35:1268–1277PubMed

39.

James RW, Pometta D (1991) The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:246–252CrossRefPubMed

40.

Steiner G, Tkac I, Uffelman KD, Lewis GF (1998) Important contribution of lipoprotein particle number to plasma triglyceride concentration in type 2 diabetes. Atherosclerosis 137:211–214CrossRefPubMed

41.

Manzato E, Zambon A, Lapolla A et al (1993) Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care 16:469–475PubMed

42.

Gabor J, Spain M, Kalant N (1980) Composition of serum very-low-density and high-density lipoproteins in diabetes. Clin Chem 26:1261–1265PubMed

43.

Lee SJ, Moye LA, Campos H, Williams GH, Sacks FM (2003) Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 167:293–302CrossRefPubMed

44.

Batal R, Tremblay M, Barrett PH et al (2000) Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 41:706–718PubMed

45.

Kashyap ML, Srivastava LS, Chen CY et al (1977) Radioimmunoassay of human apolipoprotein CII: a study in normal and hypertriglyceridemic subjects. J Clin Invest 60:171–180PubMed

46.

Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH (2002) Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 51:1041–1046CrossRefPubMed

47.

Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G (2004) Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 89:3949–3955CrossRefPubMed

Titel: Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes
verfasst von: Anne Hiukka
Jamila Fruchart-Najib
Eeva Leinonen
Hannele Hilden
Jean-Charles Fruchart
Marja-Riitta Taskinen
Publikationsdatum: 01.06.2005
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-1753-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes

Abstract

Aims/hypothesis

Subjects, materials and methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin

Springer Medizin

Abstract

Aims/hypothesis

Subjects, materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2005

Potential impact of American Diabetes Association (2000) criteria for diagnosis of gestational diabetes mellitus in Spain

Hyperinsulinaemia triggered by dietary conjugated linoleic acid is associated with a decrease in leptin and adiponectin plasma levels and pancreatic beta cell hyperplasia in the mouse

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1

Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats

Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin